Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
TWO:4123 Center Ventures is a prominent venture capital firm based in Taiwan, founded in 1957. Originally rooted in the pharmaceutical industry, the firm has evolved to support innovation and entrepreneurship across various sectors, with a particular emphasis on early-stage investments in biotech and healthcare. With assets under management totaling $1 billion, TWO:4123 Center Ventures is well-positioned to provide substantial resources and support to startups in the region. The firm operates primarily within the Asian market, leveraging its extensive network and industry expertise to foster growth and success among its portfolio companies. The leadership team at TWO:4123 Center Ventures is dedicated to integrating resources and optimizing their portfolio to drive innovation, making them a key player in the venture capital landscape of Asia.
TWO:4123 Center Ventures specializes in investing in early-stage startups, particularly in the biotech and healthcare sectors. The firm focuses on pre-seed, seed, and seed-plus stages, providing not only capital but also essential resources and support to help these startups thrive. Their investment strategy is centered around fostering innovation and entrepreneurship, ensuring that the companies they back have the tools and guidance necessary for success. By concentrating on the Asian market, TWO:4123 Center Ventures aims to tap into the region's growing potential in the biotech and healthcare industries, making strategic investments that align with their mission to drive growth and innovation.
TWO:4123 Center Ventures invests primarily in the pre-seed, seed, and seed-plus stages of startup development. This focus allows them to support companies at their earliest phases, providing the necessary resources to help them grow.
The firm has a strong emphasis on the biotech and healthcare sectors, investing in early-stage startups that are innovating within these fields. Their goal is to foster growth and success in these critical areas of the economy.
TWO:4123 Center Ventures primarily operates within the Asian market, leveraging local insights and networks to identify promising startups in the region.
While specific check sizes are not detailed, the firm focuses on early-stage investments, which typically range from smaller amounts in the pre-seed stage to larger sums in seed and seed-plus rounds.
Founders interested in pitching to TWO:4123 Center Ventures should prepare a comprehensive presentation that outlines their business model, market potential, and how their startup aligns with the firm's focus on biotech and healthcare. Specific submission guidelines are not provided, so reaching out directly for clarification may be beneficial.
The firm is committed to providing resources and support to its portfolio companies, focusing on fostering innovation and entrepreneurship to help startups succeed in their respective markets.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.